Neurotransmitter Imbalance and its Role in Parkinson’s disease: Mechanisms and Therapeutic Approaches

Gawlin Ruthwik^*
*Correspondence: Gawlin Ruthwik, Department of Psychiatry, University of Colorado Anschutz Medical Campus, Aurora, USA, USA, Email:

Introduction

Parkinson’s Disease (PD) is a chronic and progressive neurodegenerative disorder that primarily affects movement control. It is the second most common neurodegenerative disorder after Alzheimer's disease, with a significant impact on the quality of life of affected individuals. PD is characterized by the degeneration of dopaminergic neurons in the substantia nigra, a region of the brain that plays a crucial role in motor control. As dopamine-producing neurons are lost, there is a corresponding imbalance in the neurotransmitter systems of the brain, leading to a wide range of motor and non-motor symptoms, including tremors, bradykinesia, rigidity, postural instability, and cognitive decline.

The role of neurotransmitter imbalances, particularly dopamine, in Parkinson's disease is well-documented, but the disease also involves disruptions in other neurotransmitter systems, such as acetylcholine, glutamate, and serotonin. Understanding these imbalances and their contribution to both the pathophysiology and symptoms of Parkinson’s disease is crucial for the development of effective treatments. This article explores the mechanisms of neurotransmitter imbalances in PD and discusses the current and emerging therapeutic strategies that target these imbalances to alleviate symptoms and slow disease progression [1].

Description

Dopamine is a neurotransmitter that plays a key role in regulating movement, reward, and emotion. It is primarily produced in the substantia nigra, with dopaminergic neurons projecting to the striatum, a region of the brain involved in motor coordination. In Parkinson’s disease, the progressive degeneration of these dopaminergic neurons leads to a severe reduction in dopamine levels in the striatum. The loss of dopamine disrupts the balance between the two main pathways in the basal ganglia—namely the direct and indirect pathways-leading to motor symptoms such as bradykinesia (slowness of movement), rigidity, and tremors. The dopamine deficiency in PD results in an imbalance between excitatory and inhibitory signals in the brain, particularly within the motor circuits. Under normal conditions, dopamine facilitates the direct pathway, promoting movement, and inhibits the indirect pathway, which suppresses movement. In Parkinson's disease, the loss of dopamine results in the overactivity of the indirect pathway and underactivity of the direct pathway, impairing the brain's ability to initiate and control movement.

In Parkinson’s disease, there is often an increase in cholinergic activity due to a relative lack of dopamine. Dopamine typically inhibits cholinergic neurons in the striatum, but when dopamine levels are reduced, this inhibitory control is lost, leading to an overactivity of acetylcholine [2]. This imbalance can contribute to motor symptoms such as tremors and bradykinesia, as well as cognitive dysfunction and psychiatric symptoms. The cholinergic system’s role in cognitive processes such as learning and memory also explains the cognitive decline observed in advanced stages of PD. Glutamate is the major excitatory neurotransmitter in the brain and is involved in a variety of functions, including motor control and synaptic plasticity. In Parkinson’s disease, there is often an overactivation of glutamatergic pathways, particularly in the basal ganglia. This overactivity can lead to excitotoxicity, causing neuronal damage and contributing to the progression of the disease. Increased glutamate activity in the striatum is believed to contribute to the motor dysfunction seen in PD, and efforts to modulate glutamate receptors are being explored as potential therapeutic approaches.

Serotonin, a neurotransmitter involved in mood regulation and motor control, is also affected in Parkinson's disease. While the primary loss of serotonin occurs in the brainstem, there is also a reduction in serotonin levels in the basal ganglia. This imbalance is thought to contribute to mood disturbances, including depression and anxiety, which are common non-motor symptoms in Parkinson’s disease. Additionally, serotonin modulates dopaminergic activity, so its dysfunction can further exacerbate motor symptoms. The primary pathology in Parkinson’s disease is the loss of dopaminergic neurons in the substantia nigra. These neurons are crucial for maintaining proper dopamine signaling in the striatum. As the neurons degenerate, dopamine production decreases, leading to the characteristic motor symptoms. However, this degeneration does not occur in isolation, as other regions of the brain, including those involved in serotonin, acetylcholine, and glutamate signaling, also experience dysfunction [3].Neuroinflammation is another key factor in the progression of Parkinson’s disease. Activated microglia and astrocytes release pro-inflammatory cytokines, which contribute to neuronal damage and neurotransmitter imbalances. Inflammation can exacerbate the loss of dopaminergic neurons and interfere with neurotransmitter systems, further complicating the pathophysiology of the disease. The overactivation of glutamatergic signaling in Parkinson's disease can lead to excitotoxicity, which occurs when neurons are damaged due to excessive glutamate receptor activation. This process contributes to the degeneration of dopaminergic and other neurons, further exacerbating neurotransmitter imbalances and promoting disease progression. The cornerstone of Parkinson’s disease treatment is the use of dopaminergic medications to replace or mimic dopamine. Levodopa (L-DOPA) is the most effective treatment for restoring dopamine levels, as it is a precursor to dopamine that can cross the blood-brain barrier and be converted into dopamine in the brain. However, long-term use of levodopa can lead to motor complications, such as dyskinesias (involuntary movements). Other dopaminergic agents include dopamine agonists (e.g., pramipexole, ropinirole), which mimic dopamine's effects on the brain, and monoamine oxidase-B (MAO-B) inhibitors (e.g., selegiline, rasagiline), which inhibit the breakdown of dopamine, prolonging its action in the brain.

To address the imbalance between acetylcholine and dopamine in Parkinson’s disease, acetylcholinesterase inhibitors (e.g., donepezil, rivastigmine) are sometimes used. These drugs inhibit the breakdown of acetylcholine, increasing its availability in the brain and helping to alleviate cognitive symptoms. They are particularly useful in patients with Parkinson's disease dementia. As glutamate overactivity contributes to excitotoxicity and motor dysfunction, glutamate receptor antagonists are being investigated as potential treatments [4]. Amantadine, a drug that has both dopaminergic and glutamatergic effects, is used to treat early-stage Parkinson’s disease and can improve symptoms such as tremor and rigidity. Given the role of serotonin in mood regulation and motor control, Selective Serotonin Reuptake Inhibitors (SSRIs) or Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) may be used to treat depression and anxiety, which are common non-motor symptoms in Parkinson’s disease. Moreover, serotonin-dopamine interactions have led to the investigation of compounds that can modulate both neurotransmitter systems to improve motor and non-motor symptoms. In addition to traditional pharmacologic approaches, emerging therapies are being explored to address neurotransmitter imbalances in Parkinson’s disease.

Researchers are investigating the potential of gene therapy to restore dopamine production in the brain by delivering genes that encode enzymes involved in dopamine synthesis directly to the brain. This approach has shown promise in preclinical studies and early-phase clinical trials. Stem cell-based therapies aim to replace degenerated dopaminergic neurons with new, healthy neurons. While this approach is still in its early stages, it holds promise for addressing the root cause of Parkinson’s disease and restoring dopamine levels in the brain. Efforts to develop neuroprotective therapies that can slow or halt the progression of Parkinson’s disease focus on targeting the underlying mechanisms of neurodegeneration, such as oxidative stress, inflammation, and mitochondrial dysfunction [5].

Conclsuion

Neurotransmitter imbalances, particularly involving dopamine, acetylcholine, glutamate, and serotonin, play a significant role in the pathophysiology and symptoms of Parkinson’s disease. The degeneration of dopaminergic neurons is the hallmark of the disease, leading to motor dysfunction, but the involvement of other neurotransmitter systems contributes to both motor and non-motor symptoms. Current therapeutic approaches focus on restoring dopaminergic function and addressing imbalances in other neurotransmitter systems to alleviate symptoms. However, challenges remain in providing long-term, disease-modifying treatments. Ongoing research into neuroprotective strategies, gene therapy, and stem cell-based treatments offers hope for more effective therapies in the future. A deeper understanding of the complex interactions between neurotransmitter systems will be essential in the development of next-generation treatments for Parkinson’s disease.

Acknowledgement

None.

Conflict of Interest

None.

References

1. Surmeier, D. James, José A. Obeso and Glenda M. Halliday. "Selective neuronal vulnerability in Parkinson disease." Nat Rev Neurosci 18 (2017): 101-113.

Google Scholar, Crossref, Indexed at

2. Jankovic, Joseph and Eng King Tan. "Parkinson’s disease: Etiopathogenesis and treatment." J Neurol Neurosurg Psychiatry 91 (2020): 795-808.

Google Scholar, Crossref, Indexed at

3. Wirdefeldt, Karin, Hans-Olov Adami, Philip Cole and Dimitrios Trichopoulos, et al. "Epidemiology and etiology of Parkinson’s disease: A review of the evidence." Eur J Epidemiol 26 (2011): 1-58.

 Google Scholar, Crossref, Indexed at

4. Tang, Yu. "Microglial polarization in the pathogenesis and therapeutics of neurodegenerative diseases." Front Aging Neurosci 10 (2018): 154.

Google Scholar, Crossref, Indexed at

5. Dubbelaar, Marissa L., Laura Kracht, Bart JL Eggen and Erik WGM Boddeke. "The kaleidoscope of microglial phenotypes." Front Immunol 9 (2018): 1753.

Google Scholar, Crossref, Indexed at